Genetics and insurance is an area unusually exposed to rapid scientific advance, close public and political scrutiny, and popular myth. It may be leading the way towards evidence-based underwriting. This survey paper describes some of the experience gained since actuarial involvement began in the mid-1990s, particularly the vital link with genetic epidemiology. We survey the relevant aims and outputs of genetic epidemiology, mainly relating to single-gene disorders, and the use of genetic epidemiology in actuarial models. The part that actuarial models might play in evidence-based approaches to underwriting and policy-making is discussed.
No takes yet. Share an insight, caveat, or question.
Angus S. Macdonald (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: